- Home
- YRD vs DSGN Comparison
YRD vs DSGN Comparison
Compare YRD & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YRD
- DSGN
- Stock Information
- Founded
- YRD 2012
- DSGN 2017
- Country
- YRD China
- DSGN United States
- Employees
- YRD N/A
- DSGN N/A
- Industry
- YRD Finance: Consumer Services
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- YRD Finance
- DSGN Health Care
- Exchange
- YRD Nasdaq
- DSGN Nasdaq
- Market Cap
- YRD 495.5M
- DSGN 203.8M
- IPO Year
- YRD 2015
- DSGN 2021
- Fundamental
- Price
- YRD $6.55
- DSGN $3.88
- Analyst Decision
- YRD
- DSGN Buy
- Analyst Count
- YRD 0
- DSGN 2
- Target Price
- YRD N/A
- DSGN $8.00
- AVG Volume (30 Days)
- YRD 162.6K
- DSGN 145.2K
- Earning Date
- YRD 06-20-2025
- DSGN 05-07-2025
- Dividend Yield
- YRD 5.97%
- DSGN N/A
- EPS Growth
- YRD N/A
- DSGN N/A
- EPS
- YRD 2.48
- DSGN N/A
- Revenue
- YRD $795,426,969.00
- DSGN N/A
- Revenue This Year
- YRD N/A
- DSGN N/A
- Revenue Next Year
- YRD N/A
- DSGN N/A
- P/E Ratio
- YRD $2.64
- DSGN N/A
- Revenue Growth
- YRD 18.59
- DSGN N/A
- 52 Week Low
- YRD $4.12
- DSGN $2.60
- 52 Week High
- YRD $9.20
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- YRD 53.98
- DSGN 51.00
- Support Level
- YRD $5.51
- DSGN $3.25
- Resistance Level
- YRD $6.67
- DSGN $4.30
- Average True Range (ATR)
- YRD 0.44
- DSGN 0.40
- MACD
- YRD 0.10
- DSGN 0.15
- Stochastic Oscillator
- YRD 93.91
- DSGN 75.29
About YRD Yiren Digital Ltd.
Yiren Digital Ltd is an advanced, AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.